Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omicron booster

- PMLiVE

EMA recommends new manufacturing sites for COVID-19 vaccines

EMA also recommends new storage temperature for Pfizer/BioNTech vaccine

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.

Avalere Health

- PMLiVE

EU leaders debate COVID-19 vaccine export measures during virtual summit

AstraZeneca urged to ‘honour’ contract with EU before exporting doses elsewhere

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

Wearable Technologies for Detecting Pre-Symptomatic Illness and Infections

Dr. Tejaswini Mishra, Research Scientist at Stanford University School of Medicine, dives into her research on using wearable technologies for detecting COVID-19 and other diseases before patients become symptomatic. Among...

Impetus Digital

- PMLiVE

UK plans to launch new national health agency focused on tackling pandemics

The UK Health Security Agency will protect against future health threats

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

CureVac expands COVID-19 vaccine trial protocol to include variant specification

Company is aiming to ensure its vaccine efficacy data is 'meaningful' against new virus variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links